argenx Announces Results of Extraordinary General Meeting of Shareholders
Tuesday, November 18, 2025 1 min read
Key Takeaway: argenx SE announced the results of its Extraordinary General Meeting held on November 18, 2025. The sole agenda item, a remuneration policy, was overwhelmingly approved by shareholders with 95.67% voting in favor. Additionally, 91.1% of the company's share capital participated in the voting, reflecting strong support for the company's governance.
Market Sentiment Analysis
POSITIVE FACTORS
Approval of the remuneration policy by a significant majority (95.67%)
High level of shareholder participation with 91.1% of share capital represented
Demonstrates strong shareholder support and company governance
Full Press Release Details
argenx Announces Results of Extraordinary General Meeting of Shareholders
November 18, 2025 - 10:01 PM CET
Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025.
The remuneration policy, which was the sole voting item on the agenda, was approved by the required majority of votes. The Company's remuneration policy was approved by a 95.67% majority, with 91.1% of share capital represented at the Extraordinary General Meeting.